TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* HIV negative~* Willing to receive HIV test results~* Good general health~* Acceptable methods of contraception for females of reproductive potential~* Hepatitis B surface antigen negative~* Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive~* Normal thyroid stimulating hormone (TSH) level~Exclusion Criteria~* HIV vaccines or placebos in prior HIV vaccine trial~* Immunosuppressive medications within 168 days prior to first study vaccine administration~* Blood products within 120 days prior to first study vaccine administration~* Immunoglobulin within 60 days prior to first study vaccine administration~* Live attenuated vaccines within 30 days prior to first study vaccine administration~* Investigational research agents within 30 days prior to first study vaccine administration~* Subunit or killed vaccines within 14 days prior to first study vaccine administration~* Current tuberculosis prophylaxis or therapy~* Clinical depression with pharmacological treatment within the past 2 years~* Active syphilis~* Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded.~* Autoimmune disease or immunodeficiency~* Unstable asthma~* Type 1 or Type 2 Diabetes Mellitus~* Thyroid disease requiring treatment~* Serious angioedema within the past 3 years~* Uncontrolled hypertension~* Bleeding disorder~* Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period~* Seizure disorder requiring medication within the past 3 years~* Asplenia~* Mental illness that would interfere with compliance with the protocol~* Other conditions that, in the judgement of the investigator, would interfere with the study~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is Japanese.~* Smoking, healthy subject as judged by the Investigator.~* Subject smokes at least 10 commercially available mCCs per day (no brand restrictions) for the last 4 weeks, based on self-reporting.~* Subject has smoked for at least the last 3 consecutive years.~* Subject does not plan to quit smoking in the next 3 months.~Exclusion Criteria:~* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).~* The subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer) which has an impact on cytochrome P450 1 A2 (CYP1A2) or cytochrome P450 2 A6 (CYP2A6) activity.~* For women: Subject is pregnant or is breast feeding.~* For women: Subject does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 23 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- THS 2.2 Menthol (mTHS 2.2) (Type: EXPERIMENTAL): Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
- Smoking abstinence (SA) (Type: ACTIVE_COMPARATOR): Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
- Menthol Conventional Cigarette (mCC) (Type: ACTIVE_COMPARATOR): Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult males between 21 and 60 years of age who have been diagnosed with AIHH.~* Subjects must have been treated with a topical testosterone replacement therapy (typically AndroGel® or Testim®) for at least 6 months at enrollment and for not more than 2 years.~Exclusion Criteria:~* A history of idiopathic infertility due to primary hypogonadism, testicular failure, Kallmann's syndrome or any other infertility condition.~* Subjects demonstrating any clinically significant medical condition rendering the subjects infertile or marginally fertile other than AIHH.~* Men with a history of, known, or suspected prostate disease not ruled out by a prostate biopsy, or a prostate specific antigen (PSA)\>3.6 or clinical suspicion of current prostate disease.~* Men with a hematocrit in excess of 50 % or hemoglobin \>17 g/dl

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 25 mg Androxal no wash out (Type: EXPERIMENTAL): 1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
- Testim 1% (topical testosterone) (Type: ACTIVE_COMPARATOR): Testim 1% Gel applied topically for 6 months
- 25 mg Androxal wash out (Type: EXPERIMENTAL): 1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or more~* prior diagnosis of diabetes mellitus (DM)~* persistent micro-or macroalbuminuria (urinary albumin excretion\> 30 mg / g creatinine (AUC) in 3 consecutive measurements on different days)~* glycated hemoglobin \<10%~* maximum dose of ACE-I and / or ARBs.~Exclusion Criteria:~* diagnosis of autoimmune diseases, HIV, hepatitis, cancer, inflammatory disease~* pregnant or lactating patients~* glomerular filtration rate (GFR) \<30 ml/min/1, 73m2 (estimated by the MDRD and the Cockcroft-Gault formula)~* presence of kidney disease unrelated to diabetes~* chronic urinary tract infection~* diagnosis of congestive heart failure (CHF) New York Heart Association (NYHA) class III or IV~* recent history (\<6 months) unstable angina, myocardial infarction, stroke, coronary intervention~* history of alcohol and / or drugs~* mental incapacity to understand the informed consent~* intolerance to green tea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Green tea extract (Type: ACTIVE_COMPARATOR): Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
- Placebo (celulose) (Type: PLACEBO_COMPARATOR): Patients will receive four capsules of placebo (celulose) daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.~* No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.~Exclusion Criteria:~* Prior myelodysplastic disorder, or treatment-related leukemia.~* Prior myeloproliferative disease.~* Acute promyelocytic leukemia (APL).~* Prior chemotherapy for a malignant or nonmalignant disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic plaque psoriasis with or without psoriatic arthritis for at least 6 months before the Baseline Visit~* Subject has stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis~* Subject must be a candidate for systemic therapy as assessed by the investigator;~* Subject must be an acceptable candidate to receive secukinumab according to the local label for this compound.~Exclusion Criteria:~* History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis; or active skin disease other than psoriasis that could interfere with the assessment of psoriasis;~* Chronic infections including HIV, viral hepatitis (hepatitis B, hepatitis C), and/ or active tuberculosis. Subjects with a positive QuantiFERON®-TB/purified protein derivative (PPD) test result may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the subject has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment must have been initiated and maintained according to local country guidelines.~* Active systemic infection during the last 2 weeks prior to Baseline Visit (exception: common cold)~* History of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix~* Previous exposure to risankizumab~* Previous exposure to secukinumab

- Gender: None
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Risankizumab (Type: EXPERIMENTAL): Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
- Secukinumab (Type: ACTIVE_COMPARATOR): Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made~* Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled~* Prior/current treatment with any anti-VEGF intravitreal injections or macular laser (laser and/or visudyne/PDT) in the fellow eye is allowed~* Man or woman aged 18 years or more~* Patient who has been given appropriate information about the study objectives and procedures and who has given his/her written, informed consent;~Exclusion Criteria:~* Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks~* Patient who does not meet the local indication criteria for Eylea treatment.Contraindications listed in the Summary of Product Characteristics (SmPC) must be taken into account~* Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye~* Patient taking part in an interventional study at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): According to the recommendations of the Summary of Product Characteristics (SmPC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the three main coronary arteries; (~* a delayed opacification in at least one of the main coronary arteries was documented. Delayed opacification was defines as corrected TIMI frame count \> 23 fps~Exclusion Criteria:~* comorbid cardiovascular condition other than mild coronary atherosclerosis and coronary slow flow~* refusal to participate~* discontinuation of treatment~* not returning for the follow up visit

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitroglycerin (Type: ACTIVE_COMPARATOR): sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
- Nicorandil (Type: ACTIVE_COMPARATOR): nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 years ≤ Ages \<45 years~* laparoscopic unilateral ovarian cystectomy scheduled patients with benign unilateral ovarian cyst confirmed by ultrasonography~* women with regular menstruation~* women with regular menstruation cycle from 21 days to 45 days~* Proper state for laparoscopic operation (American society of Anesthesiologists Physical Status classification 1 or 2)~* Patients who signed and approved informed consent~Exclusion Criteria:~* Patients without ovarian cyst~* Patients with malignant female genital disease~* Patients with bilateral ovarian cysts~* Age ≥ 45~* Pregnancy or lactating women~* Serum AMH\<0.05 ng/ml~* Patients with endocrine disease such as thyroid abnormality, hyperprolactinemia, cushing disease, etc~* Patients with hormone replacement therapy during 3 months~* Patients who is considered to be difficult to perform the clinical trial when researchers judge

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- SurgiGuard (Type: ACTIVE_COMPARATOR): Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
- Bipolar electrocauterization (Type: NO_INTERVENTION): Bipolar electrocauterization during surgery Drug(-)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females~* Acute ischemic stroke with limb weakness, onset of symptoms within 6 hours~* Full functional independence prior to the present stroke~Exclusion Criteria:~* Unconsciousness~* Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition~* Severe illness with life expectancy less than 6 months~* Known severe kidney disorder~* Current known alcohol or illicit drug abuse or dependence~* Pregnant or breast-feeding~* Treatment with acetazolamide and methotrexate is not permitted during the infusion~* Participation in a previous clinical study within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe chronic periodontitis patients with at least two sites with pocket depth ≥ 6 mm and clinical attachment level ≥ 5 mm, with radiographic evidence of bone loss 2- or 3-wall intrabony defect depth ranging from 3 to 6 mm as detected in periapical radiographs~* The facial surface of teeth adjacent to the interproximal defect should be free of extensive recession and marginal bone loss, with at least a 4 to 5 mm band of keratinized gingiva to allow for periosteal manipulation~Exclusion Criteria:~* Pregnant women~* Subjects had \<22 permanent teeth~* Having any given systemic disease~* Taking any type of medication and/or antibiotic therapy during the 3 months before the study~* Received periodontal treatment within the past 12 months~* Current or former smokers

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- periosteal pedicle graft (Type: EXPERIMENTAL): autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
- Bioresorbable collagen membrane (Type: ACTIVE_COMPARATOR): Equine Achilles tendon collagen barrier membrane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive Skin Prick test to grass pollen~* Positive RAST to grass pollen~* Positive specific provocation test to grass pollen~Exclusion Criteria:~* Serious chronic diseases~* Other perennial allergies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Allergovit 6-grasses immunotherapy (Type: EXPERIMENTAL): Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age =\> 18 years~* Immunodeficiency secondary to a hematologic disorder~* Patient has received at least 2 Multigam IV 5% administrations~* Patient may not have had any adverse events (grade 2 or higher according to CTCAE v4.03) during the last 2 Multigam IV 5% administrations~* Patient needs at least 2 more immunoglobulin administrations~* Signed informed consent~Exclusion Criteria:~* Patient has received less than 2 Multigam IV 5% administrations~* Patient has had an adverse event (grade 2 or higher according to CTCAE v4.03) during the last 2 Multigam IV 5% administrations~* Refusal to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete